Ocumension Therapeutics Stock price
Compare with Peer Group
Is Ocumension Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.
Key metrics
Ocumension Therapeutics Stock Analysis
Analyst Opinions
8 Analysts have issued a Ocumension Therapeutics forecast:
Analyst Opinions
8 Analysts have issued a Ocumension Therapeutics forecast:
Don't miss a Thing! We will send you all news about Ocumension Therapeutics directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Ocumension Therapeutics engages in the identification, development, and commercialization of ophthalmic therapies. The company is headquartered in Suzhou, Jiangsu and currently employs 552 full-time employees. The company went IPO on 2020-07-10. The products primarily include OT-401 Yutiq fluocinolone intravitreal implant, OT-702 Boyoujing aflibercept intravitreous injection, OT-402 Visudyne, OT- 204 Ou Qin sodium hyaluronate eye drops and OT-305 Betoptic S betaxolol hydrochloride and others. The products are used to treat various anterior and posterior segment eye diseases, such as uveitis, fundus diseases, refractive correction, dry eye disease (DED), glaucoma and conjunctivitis. The firm primarily operates its business in the domestic market.
| Head office | Cayman Islands |
| CEO | Mr. Liu |
| Employees | 552 |
| Website | www.ocumension.com |


